The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

The Preventive Effects of Bcl-2 and $Bcl-_{XL}$ on Lovastatin-induced Apoptosis of C6 Glial Cells

  • Choi, Jae-Won (Department of Pharmacology, Yonsei University Wonju College of Medicine,Institute of Basic Medical Science, Yonsei University Wonju College of Medicine,The institute of Functional Biomaterials & Biotechnology, Yonsei University) ;
  • Lee, Jong-Min (Department of Pharmacology, Yonsei University Wonju College of Medicine) ;
  • Oh, Young-Jun (Department of Biology, Yonsei University College of Science)
  • Published : 2002.10.21
Download PDF
⟨ Previous Next ⟩

Abstract

It has been reported that lovastatin induced cell death and suppressed proliferation in various cell lines. In this study, we examined whether the cytotoxic effects of lovastatin could be prevented by Bcl-2 or $Bcl-_{XL}$ in C6 glial cells. Overexpression of human Bcl-2 or $Bcl-_{XL}$ prevented lovastatin $(25{\mu}M)-induced$ changes such as DNA fragmentation, chromatin condensation, disruption of cell membrane, and cleavage of poly (ADP-ribose) polymerase. Lovastatin-induced inhibition of cell proliferation was unaffected by Bcl-2 or $Bcl-_{XL}$ overexpression. These results suggest that Bcl-2 and $Bcl-_{XL}$ can prevent lovastatin-induced apoptosis in C6 glial cells, though the inhibition of proliferation remains unaffected by these proteins.

Keywords

References

  1. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322－1326, 1998 https://doi.org/10.1126/science.281.5381.1322
  2. Bredel M, Pollack IF. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res Brain Res Rev 29: 232－249, 1999 https://doi.org/10.1016/S0165-0173(98)00057-5
  3. Choi JW, Jung SE. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharm Exp Ther 289: 572－579, 1999
  4. Depraetere V, Golstein P. Dismantling in cell death: Molecular mechanisms and relationship to caspase activation. Scand J Immunol 47: 523－531, 1998 https://doi.org/10.1046/j.1365-3083.1998.00363.x
  5. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93: 1308－1318, 1999
  6. Enari M, Sakahira, H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43－50, 1998 https://doi.org/10.1038/34112
  7. Hamel W, Dazin P, Israel MA. Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Cytometry 25: 173－181, 1996 https://doi.org/10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I
  8. Hengst L, Reed SI. Translational control of p27$^kip1$ accumulation during the cell cycle. Science 271: 1861－1864, 1996 https://doi.org/10.1126/science.271.5257.1861
  9. Howe PH, Dobrowolski SF, Reddy KB, Stacey DW. Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity. J Biol Chem 268: 21448－21452, 1993
  10. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205: 1681-1687, 1994 https://doi.org/10.1006/bbrc.1994.2861
  11. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3- hydroxy- 3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 66: 1094－1100, 1980 https://doi.org/10.1172/JCI109938
  12. Lyons AB, Samuel K, Sanderson A, Maddy AH. Simultaneous analysis of immunophenotype and apoptosis of murine thymo- cytes by single laser flow cytometry. Cytometry 13: 809－821, 1992 https://doi.org/10.1002/cyto.990130803
  13. Oh YJ, Uhland-Smith A, Kim JE, O'Malley KL. Regions outside of the Bcl-2 homology domains, BH1 and BH2 protect a dopaminergic neuronal cell line from staurosporin-induced cell death. Brain Res Mol Brain Res 51: 133－142, 1997 https://doi.org/10.1016/S0169-328X(97)00229-5
  14. Reed JC. Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 89: 988－990, 1997 https://doi.org/10.1093/jnci/89.14.988
  15. Rubins RE, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157: 1616－1622, 1998 https://doi.org/10.1164/ajrccm.157.5.9709020
  16. Seabra MC. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal 10: 167－172, 1998 https://doi.org/10.1016/S0898-6568(97)00120-4
  17. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patient with cancer. Clin Cancer Res 2: 483－491, 1996
  18. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 281: 1312－1316, 1998 https://doi.org/10.1126/science.281.5381.1312
  19. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13: 1991－1999, 1996
  20. Vrtovsnik F, Couette S, Pri D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21$^{ras}$ activated, AP-1 dependent pathway. Kideny Int 52: 1016-1027, 1997. https://doi.org/10.1038/ki.1997.423
  21. Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, T. Kamei, Nishimura S, Tomimoto K. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Mol Pharmacol 54: 1－7, 1998 https://doi.org/10.1124/mol.54.1.1
  22. Zhang FL, Casey PL. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241－269, 1996 https://doi.org/10.1146/annurev.bi.65.070196.001325